For NTRK1/3 fusions, we identified 15 NTRK+ CRC cases (0.1%), 24 NTRK+ NSCLC cases (0.1%), 28 NTRK+ out of 2527 thyroid cancer cases (1.1%), 28 NTRK+ out of 14,622 breast cancer patients (0.2%), 31 NTRK+ out of 9392 glioma patients (0.3%), 10 NTRK+ out of 6627 pancreatic cancer patients (0.2%), 14 NTRK+ out of 6446 melanoma patients (0.2%), 7 NTRK+ out of 5198 prostate cancer patients (0.1%), and 5 NTRK+ out of 5900 ovarian cancer patients (0.08%). This evidence concerns the gene NTRK1 and non-small cell lung carcinoma.